-Reuters
Ensysce Biosciences Receives Notice of Award For 3 Of Multi-Year National Institute On Drug Abuse Grant For Clinical Development Of Next Generation Opioid Products With Overdose Protection; Grant Will Provide $2.8M For Phase 1 Study
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "the Company"), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of